Clinical Trials Snapshot

CD22 Redirected Autologous T Cells for ALL

Phase 1, single center, single arm, open-label pilot study to determine the feasibility and safety of a single dose administered as spilt fractions of autologous T cells expressing CD22 chimeric antigen receptors expressing tandem TCR-zeta and 4-1BB (TCR-zeta/4-1BB) co-stimulatory domains (referred to as “CART22” cells) in pediatric patients with relapsed or refractory B-cell acute lymphoblastic leukemia.

Phase 1, single center, single arm, open-label pilot study to determine the feasibility and safety of a single dose administered as spilt fractions of autologous T cells expressing CD22 chimeric antigen receptors expressing tandem TCR-zeta and 4-1BB (TCR-zeta/4-1BB) co-stimulatory domains (referred to as “CART22” cells) in pediatric patients with relapsed or refractory B-cell acute lymphoblastic leukemia.